Response to bosentan in children with pulmonary hypertension

Heart

Volumn 92, Issue 5, 2006, Pages 664-670

  Maiya, S ^a   Hislop, A A ^b   Flynn, Y ^a   Haworth, S G ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DIZZINESS; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; FLUSHING; HEADACHE; HUMAN; LUNG DISEASE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT GAIN; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFANT; MALE; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33646243000     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.072314     Document Type: Article

References (27)

1. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:75-10S.
2. Simonneau G, Galie N, Rubin U, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
3. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197-208.
4. MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther 1998;11:125-32.
5. Allen SW, Chatfield BA, Koppenhafer SA, et al. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension: association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993;148:519-22.
6. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
7. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31.
8. Holm P, Liska J, Clozel M, et al. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 1996;112:890-7.
9. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
10. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
11. Sitbon O, Badesch DB, Channick RN et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
12. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.
13. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
14. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
15. McLaughlin W, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
16. Rich S, McLaughlin W. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7.
17. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999;27:810-5.
18. Brash AR, Jackson EK, Saggese CA, et al. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 1983;226:78-87.
19. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 2003;124:1612-5.
20. Ivy DD, Doran A, Claussen L, et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004;93:943-6.
21. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9.
22. Garzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005;98:147-51.
23. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-9.
24. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-7.
25. Paul GA, Gibbs JSR, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12.
26. Li AM, Yin J, Yu CC, et al. The six-minute walk test in healthy children: reliability and validity. Eur Respir J 2005;25:1057-60.
27. Garofano RP, Barst RJ. Exercise testing in children with primary pulmonary hypertension. Pediatr Cardiol 1999;20:61-4.